Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin with 5‑FU/LV plus bevacizumab as maintenance after first‑line therapy for metastatic colorectal cancer
2007-003844-31Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic colon cancer (mCRC) and colorectal cancer (CRC) comparing Enzastaurin maintenance arm with Placebo maintenance arm (2 arms). Primary endpoint: Progression-free survival from randomization. Started Oct 2007; status: terminated.
02
Drugs
enzastaurin
03
Conditions
metastatic colon cancer (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-003844-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003844-31.